Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF

34 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Host: Riccardo Maria Inciardi, MD, PhD




Listen to Dr. Riccardo Inciardi’s summary from the ESC Preventive Cardiology 2025 meeting, where he highlights new therapies reshaping the management of cardio-kidney-metabolic (CKM) syndrome and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Watch as he breaks down the latest clinical trial data showing that SGLT2 inhibitors, GLP-1 receptor agonists, and the nonsteroidal MRA finerenone can meaningfully reduce hospitalizations, kidney disease progression, and cardiovascular mortality. A real-life patient case illustrates how combining these therapies—under the care of a multidisciplinary team—can transform outcomes.
Categoria
Cardiology
Commenta per primo questo video.

Prossimo